From MedTech devices and AI-enabled hardware to cloud platforms and AI drug discovery, AI technologies are increasingly central to inventorship and innovation across sectors. As AI becomes embedded in regulated medical technologies such as Software as a Medical Device (SaMD) and AI-enabled diagnostics, new evidentiary and regulatory considerations are emerging in patent disputes. This session reviews recent AI-related patent cases and examines how courts are shaping litigation and portfolio strategy going forward.
- How are parameters around patent eligibility evolving in AI cases.
- How litigation strategy and outcomes vary across a range of tech sectors including AI-enabled hardware, software, multifunction innovation products and MedTech.
- Address new evidentiary and regulatory considerations for handling AI in regulated technologies such as SaMD.
- How are infringement theories are being used in AI patent litigation.
- A review of recent cases like Nueral AI, LLC v. NVIDIA Corp., and Solos Technology’s complaint against Meta and EssilorLuxottica.
Speaker(s):
Erin Bell
Senior Corporate Counsel
Premier Inc
Martin McGee
Honorable Judge
State of North Carolina, Judicial District
Nirav Desai
Partner
Sterne Kessler
Rama Elluru
Senior Advisor for AI Governance and Intellectual Property
Special Competitive Studies Project
Agenda Track No.:
Track 2
Session Type:
Track
Force Inline Description:
0